{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:34:33Z","timestamp":1794108873354,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005663","name":"Council of State and Territorial Epidemiologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005262","name":"National Center for Health Statistics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005262","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kentucky Department for Public Health"},{"name":"Kentucky Office of Vital Statistics"},{"name":"Kentucky Office of the Chief Medical Examiner"},{"name":"William L. Jenkins Forensic Center, East Tennessee State University"},{"name":"Tennessee Department of Health"},{"name":"North Carolina Office of the Chief Medical Examiner"},{"name":"Maricopa County Department of Public Health"},{"name":"Maricopa County Office of the Medical Examiner"},{"name":"West Virginia Bureau for Public Health"},{"name":"West Virginia Health Statistics Center"},{"name":"West Virginia Office of the Chief Medical Examiner"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","drugandalcoholdependence.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.drugalcdep.2018.01.018","type":"journal-article","created":{"date-parts":[[2018,3,11]],"date-time":"2018-03-11T01:31:50Z","timestamp":1520731910000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"C","title":["Prevalence of gabapentin in drug overdose postmortem toxicology testing results"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4541-6574","authenticated-orcid":false,"given":"Svetla","family":"Slavova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kirschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Light","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Christy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Winecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0005","series-title":"Regulating Gabapentin as a Drug of Abuse: A Survey Study of Kentucky Pharmacists","author":"Blackmer","year":"2017"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0010","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"Bonnet","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0015","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/pds.4230","article-title":"Law enforcement-derived data on gabapentin diversion and misuse, 2002\u20132015: diversion rates and qualitative research findings","volume":"26","author":"Buttram","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0020","series-title":"Centers for Disease Control (CDC) and Prevention. National Center for Health Statistics (NCHS). Multiple Cause of Death 1999\u20132015 on CDC WONDER Online Database, Released December","first-page":"2016","author":"CDC\/NCHS","year":"2016"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0025","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/pds.1051","article-title":"An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid population","volume":"14","author":"Chen","year":"2005","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.23907\/2011.005","article-title":"Toxicology: what is routine for medicolegal death investigation purposes?","volume":"1","author":"Cina","year":"2011","journal-title":"Acad. Forensic Pathol."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0035","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.drugalcdep.2016.08.152","article-title":"Increasing abuse of gabapentin and pregabalin as reported to U.S. poison centers 2006 through 2014","volume":"171","author":"Dart","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0040","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0045","doi-asserted-by":"crossref","first-page":"e1002396","DOI":"10.1371\/journal.pmed.1002396","article-title":"Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study","volume":"14","author":"Gomes","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.04.028","article-title":"Profiles of pregabalin and gabapentin abuse by postmortem toxicology","volume":"241","author":"Hakkinen","year":"2014","journal-title":"Forensic Sci. Int."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0055","doi-asserted-by":"crossref","first-page":"266","DOI":"10.18553\/jmcp.2002.8.4.266","article-title":"Gabapentin use in a managed medicaid population","volume":"8","author":"Hamer","year":"2002","journal-title":"J. Manage. Care Pharm."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0060","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.5858\/2006-130-1274-MECAPH","article-title":"Medical examiners, coroners, and public health: a review and update","volume":"130","author":"Hanzlick","year":"2006","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/injuryprev-2016-042308","article-title":"Establishment of a comprehensive drug overdose fatality surveillance system in Kentucky to inform drug overdose prevention policies, interventions and best practices","volume":"24","author":"Hargrove","year":"2017","journal-title":"Inj. Prev."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0070","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999\u20132015","volume":"273","author":"Hedegaard","year":"2017","journal-title":"NCHS data brief"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0075","first-page":"13","article-title":"Gabapentin for substance use disorders: is it safe and appropriate?","volume":"52","author":"Howland","year":"2014","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0080","first-page":"358","article-title":"Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: a cohort study","author":"Huybrechts","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0085","series-title":"Medicines Use and Spending in the U.S. A Review of 2015 and Outlook to","author":"IMS","year":"2016"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0090","first-page":"358","article-title":"UK government to reclassify pregabalin and gabapentin after rise in deaths","author":"Iacobucci","year":"2017","journal-title":"BMJ Clin. Res. Ed."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0095","series-title":"Gabapentin for Neuropathic Pain: An Application to the 21 St Meeting of the WHO Expert Committee on Selection and Use of Essential Medicines for the Inclusion of Gabapentin on the WHO Model List of Essential Medicines","author":"Kamerman","year":"2016"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0100","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/add.13843","article-title":"Risk to heroin users of polydrug use of pregabalin or gabapentin","volume":"112","author":"Lyndon","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0105","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12891-016-1231-4","article-title":"The efficacy of preoperative administration of gabapentin\/pregabalin in improving pain after total hip arthroplasty: a meta-analysis","volume":"7","author":"Mao","year":"2016","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0110","first-page":"359","article-title":"Misuse of gabapentin and pregabalin may be underestimated","volume":"21","author":"Nahar","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0115","series-title":"2017 Addiction Health Services Research Conference","article-title":"Investigating gabapentin as a drug of abuse: associations between gabapentin prescribing, substance use disorders and opioid-related poisonings","author":"Pauly","year":"2017"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2017.1390081","article-title":"Policies to mitigate nonmedical use of prescription medications: how should emerging evidence of gabapentin misuse be addressed?","author":"Peckham","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s40261-017-0530-3","article-title":"Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population","volume":"37","author":"Peckham","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0130","series-title":"FDA Approved Labeling Text Dated 03\/01\/2011. Neurontin (gabapentin) Capsules, Tablets, Oral Solutions","author":"Pfizer","year":"2011"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0135","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0140","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3399\/bjgp12X653516","article-title":"Substance misuse of gabapentin","volume":"62","author":"Smith","year":"2012","journal-title":"Br. J. Gen. Pract."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1176\/appi.ajp.2014.14101272","article-title":"Abuse and diversion of gabapentin among nonmedical prescription opioid users in appalachian Kentucky","volume":"172","author":"Smith","year":"2015","journal-title":"Am J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0150","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/add.13324","article-title":"Gabapentin misuse, abuse and diversion: a systematic review","volume":"111","author":"Smith","year":"2016","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0155","series-title":"Timeliness of Death Certificate Data for Mortality Surveillance and Provisional Estimates, Vital Statistics Rapid Release, Special Report No.001, December 2016","author":"Spencer","year":"2016"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0160","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-145-4-200608150-00008","article-title":"Narrative review: the promotion of gabapentin: an analysis of internal industry documents","volume":"145","author":"Steinman","year":"2006","journal-title":"Ann. Internal Med."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0165","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2010\u20132014. National vital statistics reports: From the Centers for Disease Control and Prevention, National Center for Health Statistics","volume":"65","author":"Warner","year":"2016","journal-title":"Natl. Vital Stat. Syst."},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0170","doi-asserted-by":"crossref","first-page":"e3673","DOI":"10.1097\/MD.0000000000003673","article-title":"The effect of gabapentin on acute postoperative pain in patients undergoing total knee arthroplasty: a meta-analysis","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.drugalcdep.2018.01.018_bib0175","first-page":"e244","article-title":"Problematic pregabalin and gabapentin use: results from the Canada vigilance adverse reaction online database","volume":"156","author":"Zhang","year":"2015","journal-title":"Drug Alcohol Depend."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618301236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618301236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T20:47:14Z","timestamp":1660596434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618301236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":35,"alternative-id":["S0376871618301236"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.01.018","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of gabapentin in drug overdose postmortem toxicology testing results","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}